Hepatitis C (HCV) Cure and Kidney Health
NCT03407703 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50
Last updated 2018-04-18
Summary
The purpose of this study is to learn how 12 weeks of HCV treatment with elbasvir and grazoprevir (brand name Zepatier) impacts your kidney function.
Conditions
- Hepatitis C
Interventions
- DRUG
-
Elbasvir / Grazoprevir Oral Tablet [Zepatier]
HCV treatment
Sponsors & Collaborators
- collaborator INDUSTRY
-
San Francisco Veterans Affairs Medical Center
lead FED
Principal Investigators
-
Phyllis C Tien, MD · San Francisco VA Medical Center
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-03-27
- Primary Completion
- 2019-12-31
- Completion
- 2019-12-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4
NCT03381859 ·Status: WITHDRAWN ·Phase: PHASE4
-
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
NCT03823911 ·Status: COMPLETED ·Phase: PHASE4
-
HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant
NCT02902120 ·Status: COMPLETED ·Phase: PHASE4
-
A Prospective Cohort Study to Improve HCV Care in Dialysis Patients
NCT03791814 ·Status: WITHDRAWN ·Phase: PHASE4
-
Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
NCT02781649 ·Status: COMPLETED ·Phase: PHASE4
-
Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant
NCT03359746 ·Status: UNKNOWN ·Phase: PHASE4
-
Retrospective Efficacy and Safety Study With Elbasvir/Grazoprevir in HCV-infected Patients With Chronic Kidney Disease
NCT03145623 ·Status: COMPLETED
-
Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)
NCT02092350 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
The Dublin Zepatier Study
NCT02895958 ·Status: TERMINATED ·Phase: PHASE4
-
Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4
NCT02886624 ·Status: COMPLETED ·Phase: PHASE2
-
Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in G1b Treatment-Naïve, HCV-Infected Patients
NCT03496233 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062)
NCT02105688 ·Status: COMPLETED ·Phase: PHASE3
-
EBR/GZR for HCV-1b Patients Receiving Hemodialysis
NCT03420300 ·Status: COMPLETED ·Phase: PHASE4
-
8 Weeks Versus 12 Weeks of Elbasvir/Grazoprevir in Treatment-naïve CHC With Mild Fibrosis
NCT03186365 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068)
NCT02105701 ·Status: COMPLETED ·Phase: PHASE3
-
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
NCT01937975 ·Status: COMPLETED ·Phase: PHASE1
-
Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel
NCT03144440 ·Status: COMPLETED
-
Grazoprevir and Elbasvir Without Ribavirin for 12 Weeks in Patients With HCV-related Cryoglobulinemic Nephropathy
NCT03433326 ·Status: UNKNOWN
-
Direct-acting Antiviral Therapy to Prevent HCV Infection for HCV Positive Donor to HCV Negative Recipient Kidney Transplant
NCT03093740 ·Status: WITHDRAWN ·Phase: PHASE4
-
A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir
NCT03144635 ·Status: COMPLETED ·Phase: PHASE4
-
Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Chronic Hepatitis C Participants With Child-Pugh (CP)-B Hepatic Insufficiency (MK-5172-059)
NCT02115321 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Impact of Hepatitis C Therapy and Bone Health
NCT03221582 ·Status: TERMINATED ·Phase: PHASE4
-
An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus in Participants Who Are Co-Infected With Human Immunodeficiency Virus:C-EDGE CO-INFXN (MK-5172-061)
NCT02105662 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naïve Participants With Chronic Hepatitis C Virus Genotypes 1, 4, and 6 (MK-5172-060)
NCT02105467 ·Status: COMPLETED ·Phase: PHASE3
-
Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017)
NCT01667081 ·Status: COMPLETED